Brian Holdorf.

EL SEGUNDO, Calif.—Brian Holdorf, a long-time compounding pharmacist who joined OSRX, an affiliate of Ocular Science when it was formed in 2019, has been named chief formulation officer for the company. According to Anthony Sampietro, Ocular Science CEO, Holdorf has helped transform OSRX into a PCAB-accredited 503A compounding pharmacy that today produces customized ophthalmic formulations for physicians and their patients across the country. After receiving a Doctor of Pharmacy from the University of Montana in 2004, Holdorf worked as an inpatient clinical pharmacist at a 200-bed level II hospital, a home infusion pharmacist and specialized in compounding intrathecal injections.

“Brian is an absolute wizard in terms of tailor-making and innovating compounded formulations—nobody does it better,” said Sampietro. “His precision and commitment to quality is a core reason we reached record-breaking revenue in 2022 and our national footprint continues to expand year after year. Brian is undoubtedly one of the leading pharmaceutical minds in the country.”

Holdorf’s primary focus for OSRX in 2023 will be enhancing the organization to better align with Good Manufacturing Practice regulations and scaling OSRX processes to meet physician demand. He will also continue his specialized education by attending national conferences regarding quality improvement and the evolving pharmacy landscape.

“I’ve worked with Brian for nine years and watched him create solutions for patients and providers time and time again. He has the ability to ‘think outside the box’ and apply scientific principles in unison, a rare talent,” said OSRX chief pharmacy officer Amy Frost.

“Brian has never faltered to put patient safety at the forefront of everything we do and the satisfaction of our customers is a testament to that quality. I’m excited that his dedication and industry expertise are being rewarded by this promotion, and look forward to more great things to come of Brian’s work.”